Repurposing DPP4 Inhibitors for Target Therapy Resistance in Renal Cell Carcinoma | Oncotarget



September 19, 2023

  • Share
  • Oncotarget published this trending editorial on September 15, 2023 in Volume 14, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma" by Kuniko Horie and Satoshi Inoue from the Division of Systems Medicine and Gene Therapy, Research Center for Genomic Medicine, Saitama Medical University, Hidaka, Saitama, Japan; Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Tokyo, Japan. DOI - Correspondence to - Satoshi Inoue - Sign up for free Altmetric alerts about this article - Subscribe for free publication alerts from Oncotarget - Keywords - cancer, renal cell carcinoma (RCC), tyrosine kinase inhibitor (TKI), Dipeptidyl peptidase IV (DPP4), drug resistance, drug repurposing About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - X - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchCell ScienceDrug Discovery

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.